Journey Medical Corp (DERM): Shareholders' Equity
$31.85M
As of 2025-12-31
$32.11M
As of 2026-06-30
+23.3%
3-year compound annual growth
+25.4%
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $31.85M | +58.7% | 2026-03-26, Balance as of period end |
| 2024-12-31 | $20.07M | -1.4% | 2026-03-26, Balance as of period end |
| 2023-12-31 | $20.35M | +19.8% | 2025-03-27, Balance as of period end |
| 2022-12-31 | $16.98M | -59.6% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $42.04M | +308.5% | 2023-03-31, Balance as of period end |
| 2020-12-31 | $10.29M | n/a | 2022-03-28, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Journey Medical Corp (DERM) | 2025-12-31 | $31.85M | +58.7% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $346.18M | +73.5% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $305.72M | -34.1% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $49.87M | +119.3% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $35.27M | +86.0% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $64.72M | -49.8% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $59.02M | +28.0% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $174.13M | -57.9% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $89.83M | +47.9% |
Compare DERM, TNGX, NUVB, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗